Reversibility of oncogene-induced cancer

Current Opinion in Genetics and Development

Volumn 14, Issue 1, 2004, Pages 37-42

  Felsher, Dean W ^a  

^a STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER; CANCER GENETICS; CANCER THERAPY; CARCINOGENESIS; DNA REPAIR; GENE; GENE ACTIVATION; GENE INACTIVATION; GENETIC DAMAGE; HUMAN; NONHUMAN; ONCOGENE; ONCOGENE BCR ABL; ONCOGENE ERB; ONCOGENE MET; ONCOGENE MYC; ONCOGENE NEU; ONCOGENE RAS; ONCOGENE WNT; PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0842303173     PISSN: 0959437X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gde.2003.12.008     Document Type: Review

References (35)

1. Bishop J.M. Molecular themes in oncogenesis. Cell. 64:1991;235-248.
2. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell. 100:2000;57-70.
3. Cory S. Activation of cellular oncogenes in hemopoietic cells by chromosome translocation. Adv Cancer Res. 47:1986;189-234.
4. Ferrando A.A., Neuberg D.S., Staunton J., Loh M.L., Huard C., Raimondi S.C., Behm F.G., Pui C.H., Downing J.R., Gilliland D.G.et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell. 1:2002;75-87.
5. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S.et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:2001;10869-10874.
6. DeRisi J., Penland L., Brown P.O., Bittner M.L., Meltzer P.S., Ray M., Chen Y., Su Y.A., Trent J.M. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet. 14:1996;457-460.
7. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X.et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 403:2000;503-511.
8. Tlsty T.D. Genomic instability and its role in neoplasia. Curr Top Microbiol Immunol. 221:1997;37-46.
9. van Gent D.C., Hoeijmakers J.H., Kanaar R. Chromosomal stability and the DNA double-stranded break connection. Nat Rev Genet. 2:2001;196-206.
10. Felsher D.W. Opinion: cancer revoked: oncogenes as therapeutic targets. Nat Rev Cancer. 3:2003;375-379.
11. Chin L., Tam A., Pomerantz J., Wong M., Holash J., Bardeesy N., Shen Q., O'Hagan R., Pantginis J., Zhou H.et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 400:1999;468-472.
12. Felsher D.W., Bishop J.M. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 4:1999;199-207.
13. Huettner C.S., Zhang P., Van Etten R.A., Tenen D.G. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 24:2000;57-60.
14. Pelengaris S., Littlewood T., Khan M., Elia G., Evan G. Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion. Mol Cell. 3:1999;565-577.
15. Wang R., Ferrell L.D., Faouzi S., Maher J.J., Bishop J.M. Activation of the Met receptor by cell attachment induces and sustains hepatocellular carcinomas in transgenic mice. J Cell Biol. 153:2001;1023-1034.
16. D'Cruz C.M., Gunther E.J., Boxer R.B., Hartman J.L., Sintasath L., Moody S.E., Cox J.D., Ha S.I., Belka G.K., Golant A.et al. c-MYC induces mammary tumorigenesis by means of a preferred pathway involving spontaneous Kras2 mutations. Nat Med. 7:2001;235-239.
17. Fisher G.H., Wellen S.L., Klimstra D., Lenczowski J.M., Tichelaar J.W., Lizak M.J., Whitsett J.A., Koretsky A., Varmus H.E. Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev. 15:2001;3249-3262.
18. Jain M., Arvanitis C., Chu K., Dewey W., Leonhardt E., Trinh M., Sundberg C.D., Bishop J.M., Felsher D.W. Sustained loss of a neoplastic phenotype by brief inactivation of MYC. Science. 297:2002;102-104 We examined, using the Tet system, if the brief inactivation of an oncogene was capable of inducing sustained tumor regression. We showed that even inactivating the MYC oncogene for as short as a few days in osteogenic sarcomas results in their differentiation. Surprisingly, reactivation of MYC failed to restore their neoplastic properties both in vitro or in vivo, and instead induces apoptosis. These results suggest the possibility that oncogene inactivation can result in a change in the differentiative state of tumor cells and in this new epigenetic context oncogene activation fails to be capable of sustaining tumorigenesis.
19. Pelengaris S., Khan M., Evan G.I. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 109:2002;321-334 These results provide compelling in vivo evidence that the MYC oncogene can be restrained from causing tumorigenesis through apoptosis. Blocking the ability of MYC to induce apoptosis was shown to dramatically increase the facility by which MYC activation induced tumorigenesis. In addition, the authors demonstrated that upon MYC inactivation, tumors undergo regression associated with the loss of angiogenesis, changes in expression of cell adhesion molecules and the induction of apoptosis.
20. Moody S.E., Sarkisian C.J., Hahn K.T., Gunther E.J., Pickup S., Dugan K.D., Innocent N., Cardiff R.D., Schnall M.D., Chodosh L.A. Conditional activation of Neu in the mammary epithelium of transgenic mice results in reversible pulmonary metastasis. Cancer Cell. 2:2002;451-461.
21. Gunther E.J., Moody S.E., Belka G.K., Hahn K.T., Innocent N., Dugan K.D., Cardiff R.D., Chodosh L.A. Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. Genes Dev. 17:2003;488-501 Hence, oncogene inactivation can induce tumor regression even in the context of the loss of p53 function, but tumors do not exhibit sustained tumor regression. Thus, there are likely to be specific genetic contexts when oncogene inactivation can induce sustained tumor regression. Understanding the mechanism by which loss of p53 function facilitates the relapse of tumors will be very important in the design of therapies that target oncogenes for the treatment of cancer.
22. Ewald D., Li M., Efrat S., Auer G., Wall R.J., Furth P.A., Hennighausen L. Time-sensitive reversal of hyperplasia in transgenic mice expressing SV40 T antigen. Science. 273:1996;1384-1386.
23. Gossen M., Bujard H. Tight control of gene expression in mammalian cells by tetracycline- responsive promoters. Proc Natl Acad Sci USA. 89:1992;5547-5551.
24. Karlsson A., Giuriato S., Tang F., Fung-Weier J., Levan G., Felsher D.W. Genomically complex lymphomas undergo sustained tumor regression upon MYC inactivation unless they acquire novel chromosomal translocations. Blood. 101:2003;2797-2803 Our results suggest first that even genomically complex and unstable tumors undergo tumor regression upon the inactivation of a single oncogene. In addition, we demonstrated that tumors can escape dependence upon the requirement of even an oncogene that initiated tumorigenesis. The mechanism of tumor relapse appears to be associated with the acquisition of novel chromosomal translocations.
25. Felsher D.W., Bishop J.M. Transient excess of MYC activity can elicit genomic instability and tumorigenesis. Proc Natl Acad Sci USA. 96:1999;3940-3944.
26. Giuriato S., Felsher D.W. How cancers escape their oncogene habit. Cell Cycle. 2:2003;329-332.
27. Weinstein I.B. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science. 297:2002;63-64.
28. Baudino T.A., McKay C., Pendeville-Samain H., Nilsson J.A., Maclean K.H., White E.L., Davis A.C., Ihle J.N., Cleveland J.L. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression. Genes Dev. 16:2002;2530-2543.
29. Spruck C.H., Won K.A., Reed S.I. Deregulated cyclin E induces chromosome instability. Nature. 401:1999;297-300.
30. Denko N.C., Giaccia A.J., Stringer J.R., Stambrook P.J. The human Ha-ras oncogene induces genomic instability in murine fibroblasts within one cell cycle. Proc Natl Acad Sci USA. 91:1994;5124-5128.
31. Karlsson A., Deb-Basu D., Cherry A., Turner S., Ford J., Felsher D.W. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci USA. 100:2003;9974-9979.
32. Holtzer H., Biehl J., Yeoh G., Meganathan R., Kaji A. Effect of oncogenic virus on muscle differentiation. Proc Natl Acad Sci USA. 72:1975;4051-4055.
33. Boettiger D., Soltesz R., Holtzer H., Pacifici M. Infection of chick limb bud presumptive chondroblasts by a temperature-sensitive mutant of Rous sarcoma virus and the reversible inhibition of their terminal differentiation in culture. Mol Cell Biol. 3:1983;1518-1526.
34. Moss P.S., Honeycutt N., Pawson T., Martin G.S. Viral transformation of chick myogenic cells. The relationship between differentiation and the expression of the SRC gene. Exp Cell Res. 123:1979;95-105.
35. Xie W., Chow L.T., Paterson A.J., Chin E., Kudlow J.E. Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified epithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene. 18:1999;3593-3607.